Hans Scientific Invests $2 Billion to Expand U.S. Drug Manufacturing

URLhttps://pharmasource.global/content/news/cdmo-news
SourcePharma Source
Date Published10/01/2025

Additional Reshoring Information:

Company/Division name Hans Scientific
Parent companyHans Scientific
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Reshoring
Year reshoring announced:2025
Year reshoring implemented or to be implemented:2025
Capital investment ($):2000
State(s) reshored to:MI
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharma
What non-domestic negative factors made offshoring less attractive?Tariffs
What domestic positive factors made reshoring more attractive?Eco-system synergies, Image/brand, Proximity to customers/market
Find Reshoring Articles